跳至主要内容
临床试验/TCTR20211229003
TCTR20211229003招募中4 期

Switching to Dolutegravir bases regimens vs Rilpivirine based regimens in antiretroviral experienced patients with virological supression: randomized controlled trial, open label

/A0 个研究点目标入组 210 人开始时间: 2021年12月29日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Patients more than 18 years of age who have previously received antiretroviral regimens Tenofovir/Emtricitabine/Efavirenz for more than or equal to 6 months and have an HIV-1 RNA viral load of less than 20 copies/ml within 6 months before the study.

排除标准

  • 1. Infected with HIV 2 RNA, 2. Evidence that one of the antiretroviral drug resistance genes is found, 3. Drug interactions such as proton pump inhibitors, H2 receptor antagonists, rifampicin, and anticonvulsants, 4. Being pregnant or breastfeeding, 5. The renal function calculated from the Cockcroft Gault equation is less than 60 mL/min, 6. Have a psychiatric illness

研究者

发起方
/A

相似试验